申请人:CARA THERAPEUTICS INC
                            
                            
                                公开号:WO2009120660A2
                            
                            
                                公开(公告)日:2009-10-01
                            
                            The invention provides compounds having the structure of formula I, and prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof, wherein A, Y and the groups R1, R2, R3 and R4 are defined in the specification. These compounds can be administered in pharmaceutical formulations to modulate cannabinoid receptor activity for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.